SBIR-STTR Award

Development of Gel Dosimeters for Radiotherapy
Award last edited on: 2/16/04

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$104,661
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
John A Adamovics

Company Information

Heuris Pharma LLC (AKA: Heuris Inc)

412 Sunset Road
Skillman, NJ 08558
   (908) 874-4215
   N/A
   N/A
Location: Single
Congr. District: 07
County: Somerset

Phase I

Contract Number: 1R43CA088595-01A2
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2002
Phase I Amount
$104,661
The long-term objective of this project is to develop a three-dimensional dosimeter for verifying complex conformal radiotherapeutic treatment. The overall criteria is that the dosimeter formulation must be as sensitive as but more stable than the currently available dosimeter, BANG-3 from MGS. An extensive screening study of radiolytically oxidizable and reducible compounds in aqueous gels and nonaqueous polymers was performed. From these studies we have identified several formulations that should meet the criteria of being equivalent to and more stable than the BANG-3 dosimeter. Based on these preliminary results our experimental plan calls for additional diffusion studies using a micro beam tomographic optical scanner. In addition, the color intensity versus absorbed dose, effect of concentration on G value, dependence of photon energy and dose rate, and signal stability will all be measured using a spectrophotometer at 632 nm. If the above criteria are met a full scale dosimeter will be irradiated and evaluated on a tomographic optical scanning system.

Thesaurus Terms:
biomedical equipment development, computer assisted patient care, electronic recording system, mathematical model, mathematics, radiation therapy dosage patient care planning bioimaging /biomedical imaging, spectrometry

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----